STOCKS TELEGRAPH

Tag: Nasdaq: ATOS

  • 3 Stocks Flashing Bullish Signals: Cardiol Therapeutics (CRDL), Amarin (AMRN), Atossa Therapeutics (ATOS)

    3 Stocks Flashing Bullish Signals: Cardiol Therapeutics (CRDL), Amarin (AMRN), Atossa Therapeutics (ATOS)

    The biotechnology sector stands at a critical intersection where breakthrough innovation must be matched by operational precision. As funding environments tighten and expectations from investors and partners intensify, organizations are being challenged to deliver measurable progress with greater transparency. Long-term success increasingly depends on strategic capital deployment, well-structured clinical pathways, and proactive collaboration with regulatory bodies to maintain momentum and trust.

    Cardiol Therapeutics Inc. (CRDL)

    Cardiol Therapeutics Inc. (NASDAQ: CRDL) is entering a pivotal stage in its development trajectory as its lead asset advances toward late-stage completion. With growing clarity around clinical timelines and execution, the company is positioning itself for a potential value inflection tied to upcoming trial milestones.

    Market Momentum

    As of May 4, 2026, CRDL closed at $1.33, down 2.92%, with trading volume (546,678 shares) below its average of 678,166 shares—indicating moderate selling pressure without a sharp spike in activity. With a market cap of $148.535M and a beta of 0.43, the stock continues to demonstrate relatively low volatility. It remains within its 52-week range ($0.8800–$1.71), while a 1-year target estimate of $7.49 reflects significant upside potential driven by clinical catalysts.

    Clinical Progress: MAVERIC Trial

    The Phase III MAVERIC trial evaluating CardiolRx™ for recurrent pericarditis has reached approximately 75% patient enrollment, marking meaningful progress toward study completion. The trial is randomized, double-blind, and placebo-controlled, designed in collaboration with the FDA following Phase II discussions. To support timely enrollment, the company plans to activate additional U.S. clinical sites, with full enrollment expected by late Q2 or potentially extending into Q3 2026.

    Clinical Foundation

    MAVERIC builds on encouraging Phase II data, which demonstrated reductions in pain, inflammation, and recurrence rates. These findings, presented at major cardiovascular conferences, provide a strong clinical foundation and support the potential for positive Phase III outcomes.

    Outlook

    With enrollment nearing completion, Cardiol is approaching a key catalyst window. Successful Phase III results could enable regulatory advancement and serve as a major driver of valuation re-rating.

    Amarin Corp ADR (AMRN)

    Amarin Corp ADR (NASDAQ: AMRN) started the day on May 04, 2026, with a price increase of 1.21% at $14.24. During the day, the stock rose to $14.42 and sunk to $13.81. Taking a more long-term approach, AMRN posted a 52-week range of $9.44-$20.90.

    The Healthcare Sector giants’ yearly sales growth during the last 5-year period was -14.55%. Meanwhile, its Annual Earning per share during the time was -14.55%.  Nevertheless, stock’s Earnings Per Share (EPS) this year is 61.11%. This publicly-traded company’s shares outstanding now amounts to $20.98 million, simultaneously with a float of $20.89 million. The organization now has a market capitalization sitting at $298.76 million.

    Atossa Therapeutics Inc (ATOS)

    As of May 04, 2026, Atossa Therapeutics Inc (NASDAQ: ATOS) got off with the flyer as it spiked 9.94% to $5.86. During the day, the stock rose to $5.97 and sunk to $5.33. Taking a more long-term approach, ATOS posted a 52-week range of $3.76-$19.35.

    In the past 5-years timespan, the Healthcare sector firm’s annual sales growth was 32.87%. Meanwhile, its Annual Earning per share during the time was 32.87%.  Nevertheless, stock’s Earnings Per Share (EPS) this year is 5.53%. This publicly-traded company’s shares outstanding now amounts to $8.61 million, simultaneously with a float of $8.52 million. The organization now has a market capitalization sitting at $50.46 million.

  • 3 Stocks to Watch Closely: Atossa Therapeutics Inc (ATOS), AlphaTON Capital Corp (ATON), Hillcrest Energy Technologies Ltd. (HLRTF)

    3 Stocks to Watch Closely: Atossa Therapeutics Inc (ATOS), AlphaTON Capital Corp (ATON), Hillcrest Energy Technologies Ltd. (HLRTF)

    As financial markets continue to evolve, investors are refining their approach to evaluating opportunities in the emerging and small-cap segment. Movements in share valuations and fluctuations in trading activity often serve as indicators of shifting confidence. Monitoring volatility patterns, recent market performance, and the prevailing investment climate helps reveal how these companies are reacting to ongoing economic and market changes.

    Atossa Therapeutics Inc (ATOS)

    Atossa Therapeutics Inc (NASDAQ: ATOS)‘s stock price has plunged by 2.84%relation to the previous closing price of $4.57. Nevertheless, the company has seen a -0.42% plunge in its stock price over the last five trading sessions, with a -11.99% decline in the past month and a -60.80% plunge in the past quarter. The volatility ratio for the week is 8.81%, and the volatility levels for the past 30 days are at 8.87% for ATOS. The simple moving average for the past 20 days is 6.71% for ATOS’s stock, with a -58.00% simple moving average for the past 200 days.

    ATOS Trading at -32.33% from the 50-Day Moving Average

    After a stumble in the market that brought ATOS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -75.71% of loss for the given period. Volatility was left at 8.87%; however, over the last 30 days, the volatility rate increased by 8.81%.

    AlphaTON Capital Corp (ATON)

    AlphaTON Capital Corp (NASDAQ: ATON) has experienced a rise in its stock price by 1.84% compared to its previous closing price of $0.39. However, the company has seen a gain of 4.09% in its stock price over the last five trading days, with a -25.52% drop in the past month and a -75.81% drop in the past quarter. The volatility ratio for the week is 13.09%, and the volatility levels for the past 30 days are 12.44% for ATON. The simple moving average for the past 20 days is -8.22% for ATON’s stock, with a -90.74% simple moving average for the past 200 days.

    ATON Trading at -35.53% from the 50-Day Moving Average

    After a stumble in the market that brought ATON to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with 97.48% of loss for the given period. Volatility was left at 12.44%; however, over the last 30 days, the volatility rate increased by 13.09%.

    Hillcrest Energy Technologies Ltd. (HLRTF)

    Hillcrest Energy Technologies Ltd. (HLRTF) has been strengthening its European presence by appointing Otmar Bitsche as Vice President of European Business Development. With more than three decades of experience in EV powertrain systems, including leadership roles at Porsche, Bitsche is expected to help drive the adoption of Hillcrest’s ZVS technology among European automotive manufacturers and industrial partners.

    Market Momentum

    As of March 10, HLRTF is trading at $0.1249, reflecting a 4.66% daily decline. Despite the drop, the company’s stock remains significantly above its 52-week low of $0.0490, demonstrating the volatility typical of emerging technology companies.

    Strategic Expansion

    Hillcrest’s collaboration with Systematec GmbH provides engineering support and validation capabilities aimed at accelerating integration of its inverter technology into automotive and industrial applications.

    Sector Outlook

    Europe remains one of the largest markets for EV development and electrification initiatives, creating opportunities for innovative power electronics solutions.

  • Atossa Therapeutics (ATOS) Stock Shows Little Substance

    Atossa Therapeutics (NASDAQ: ATOS) is an early-stage biopharmaceutical that is slowly making progress with a Covid-19-related treatment. ATOS stock has been declining, given that investors have little to latch onto at the present moment.

    Bleak Financial Outlook for ATOS

    Atossa Therapeutics (ATOS) has not had a good year in the stock market, with ATOS stock price decline of over 75% seen in the last 12 months alone. This lack of confidence by market participants comes as a direct result of poor fundamentals, and little substance to hold on to that would warrant investing one’s capital in. Its EPS of -$0.05 marginally beat the analyst consensus of -$0.06. Moreover, its operating expenses saw a reduction from $7,000 to $6,595 on a year-on-year basis. Its cash holdings have decreased since the prior quarter from $131,100 to $125,500. This clearly points to financing challenges for large-scale drug development.

    Atossa Therapeutics Pipeline and Progress

    Financials, at this point of the company’s lifecycle, do not reflect the inherent value it holds, which is typical of an early-stage bio-pharmaceutical. The company has initiated a number of procedures in the development process of its AT-H201 drug candidate, after the completion of parts B and C of its phase 1/2a clinical trial. Although this stage of the development process is far too early for an opinion to be formed about the drug’s viability, it is progress nonetheless. To add, Atossa also entered into an agreement with a US venture capital firm that will assist the company in relation to operations, personnel, and intellectual property.

    Conclusion

    At present, ATOS stock has little substance going for it, the result of which the market does not have a reason to be confident about its prospects. However, progress is slow, which is better than its affairs being at a complete standstill.

  • Why Atossa Therapeutics, Inc. (Nasdaq: ATOS) stock tumbled in the pre-market trading?

    Why Atossa Therapeutics, Inc. (Nasdaq: ATOS) stock tumbled in the pre-market trading?

    Atossa Therapeutics, Inc. (Nasdaq: ATOS) stock dropped down -38.46 to $0.88 in the Early hour’s session today after a clinical-stage biopharmaceutical corporation looking to find and grow novel drugs in areas of substantial unmet medical need with a current emphasis on breast cancer and COVID-19, revealed the offering of an underwritten public offering with estimated cumulative gross proceeds of $20.0 million before deducting underwriting discounts, commissions.

    The shares issued by the Corporation comprise of I 14,575,000 shares, each consisting of one share of common stock and 0,75 Warrants for the acquisition of one share of common stock for $1.00 each unit and (ii) 5,425 units, each consisting of one share of Series C Convertible Preferred Stock with a fixed valuation of $1,000 each share and convexed. The Warrants will have an exercise price of $1.00 per share, will be automatically enforceable, and will expire four years from the date of issue.

    Shares of Common Stock, Preferred Stock, and associated Warrants can only be acquired together in the bid but will be distributed separately and will be instantly separable upon issuance. According to the standard closing terms, the offer is scheduled to close on or around 11 December 2020.

    Following the deal, Maxim Group LLC serves as the sole book manager.

    Atossa Therapeutics has given Maxim Group LLC a 45-day option to buy up to an extra 3,000,000 shares of Common Stock and Warrants to purchase up to an additional 2,250,000 shares of Common Stock a public offering price of fewer discounts and commissions.

  • Atossa Therapeutics, Inc. (ATOS) provides promising findings from the Phase 1 Clinical Trial of AT-301 Nasal Spray for COVID-19

    Atossa Therapeutics, Inc. (ATOS) provides promising findings from the Phase 1 Clinical Trial of AT-301 Nasal Spray for COVID-19

    Atossa Therapeutics, Inc. (Nasdaq: ATOS) a biotech giant with a focus on breast cancer and COVID-19, today announced blinded results from its Phase 1 clinical trial using Atossa ‘s patented AT-301, delivered through a nasal spray.

    In this study, AT-301 was found to be safe and well-received at two different dose levels over 14 days, in both single and multiple-dose formulations. For patients experiencing symptoms with COVID-19, AT-301 is being created to be used at home. In order to treat COVID-19 at home, there are currently no FDA-approved therapies.

    Atossa helps to determine potential collaborators who are designing diagnostic tests for COVID-19 so that AT-301 nasal spray can be co-developed and promoted with the purpose of making accessible AT-301 therapy when a person shows symptoms and test positive for the coronavirus.

    Atossa plans to further improve its nasal spray to prevent infection with COVID-19, specifically for all of those living in high-risk environments such as COVID-19 infected patients, health care workers, and emergency respondents and teachers.

    Although some manufacturers are still developing a vaccine for SARS-CoV-2, Atossa considers that therapies such as AT-301 provide a major market opportunity. The production and availability of conventional vaccines can also take years. Surveys have found that when a conventional vaccine is initially available, many people would not receive a vaccine 100%, particularly if multiple types of Coronavirus appear.

    The stock of the Healthcare sector started trading yesterday at $1.33. During the session, it climbed to $1.49 and dropped to $1.25 before closing at the price of $1.36. The stock with a market capitalization of $14.47M had a volume of 280.54 k.